Who owns RLAY?
Institutional ownership of Relay Therapeutics Inc. from Form 13F, Q2 2026
258 institutional managers reported holding Relay Therapeutics Inc. (RLAY) in Form 13F filings for Q2 2026, with 246,758,031 shares worth $4.6B. The largest reported holder was SB Investment Advisers (uk) LTD. Managers that filed both quarters added a net 61,480,319 shares (+33.3%). 48 opened new positions and 31 sold out.
- Funds holding
- 258
- Value held
- $4.6B
- New / sold out
- 48 / 31
- Net shares, same filers
- +33.3%
Holdings as of June 30, 2026, the end of Q2 2026. Managers have 45 days after a quarter ends to file Form 13F (by August 14, 2026 for Q2 2026), so positions may have changed since.
Largest holders of RLAY
| Fund | Value | Share of 13F holdings | Shares | Move |
|---|---|---|---|---|
| SB Investment Advisers (uk) LTD | $522M | 11.3% | 27,904,963 | Unchanged |
| FMR LLC | $376M | 8.1% | 20,110,113 | Added |
| Casdin Capital, LLC | $300M | 6.5% | 16,035,240 | Added |
| BlackRock, Inc. | $286M | 6.2% | 15,288,202 | Added |
| Perceptive Advisors LLC | $264M | 5.7% | 14,106,187 | Added |
| Commodore Capital LP | $225M | 4.9% | 12,000,000 | Trimmed |
| State Street Corp | $189M | 4.1% | 10,125,381 | Added |
| Vanguard Capital Management LLC | $168M | 3.6% | 8,964,423 | Added |
| Price T Rowe Associates Inc | $144M | 3.1% | 7,708,507 | Added |
| Nextech Invest Ltd. | $127M | 2.7% | 6,776,506 | Added |
| Bellevue Group AG | $116M | 2.5% | 6,185,970 | Trimmed |
| Geode Capital Management, LLC | $88.4M | 1.9% | 4,726,576 | Added |
| TCG Crossover Management, LLC | $80.0M | 1.7% | 4,273,356 | Unchanged |
| Morgan Stanley | $72.1M | 1.6% | 3,851,071 | Added |
| Siren, L.L.C. | $68.3M | 1.5% | 3,650,000 | New |
| Goldman Sachs Group Inc | $63.8M | 1.4% | 3,408,701 | Added |
| Westfield Capital Management Co LP | $62.6M | 1.4% | 3,343,496 | New |
| Kynam Capital Management, LP | $61.7M | 1.3% | 3,300,000 | Added |
| Dimensional Fund Advisors LP | $58.5M | 1.3% | 3,127,564 | Added |
| Spruce Street Capital LP | $55.8M | 1.2% | 2,984,125 | Unchanged |
| Vanguard Portfolio Management LLC | $54.1M | 1.2% | 2,892,785 | Added |
| Baker Bros. Advisors LP | $52.9M | 1.1% | 2,826,783 | Added |
| Bank of America Corp | $50.4M | 1.1% | 2,695,108 | Added |
| MPM Bioimpact LLC | $45.2M | 1.0% | 2,415,672 | Added |
| Arrowstreet Capital, Limited Partnership | $41.9M | 0.9% | 2,238,929 | Added |
Share of 13F holdings is each fund's shares as a share of the 246,758,031 RLAY shares all 13F filers reported, not of shares outstanding.
Biggest buyers in Q2 2026
- FMR LLC Added+$307M
- Price T Rowe Associates Inc Added+$108M
- Perceptive Advisors LLC Added+$81.5M
- State Street Corp Added+$72.8M
- Siren, L.L.C. New+$68.3M
- Westfield Capital Management Co LP New+$62.6M
- Morgan Stanley Added+$45.3M
- BlackRock, Inc. Added+$43.3M
- Alliancebernstein L.p. Added+$39.3M
- Pictet Asset Management Holding SA Added+$38.9M
Biggest sellers in Q2 2026
- Commodore Capital LP Trimmed-$93.5M
- Balyasny Asset Management L.P. Trimmed-$54.7M
- Bellevue Group AG Trimmed-$30.1M
- EcoR1 Capital, LLC Trimmed-$22.6M
- Kalehua Capital Management LLC Sold out-$17.9M
- Marshall Wace, LLP Trimmed-$17.3M
- Adage Capital Partners GP, L.l.c. Trimmed-$15.9M
- Two Sigma Investments, LP Trimmed-$12.5M
- Renaissance Technologies LLC Trimmed-$9.0M
- Logos Global Management LP Trimmed-$7.5M
The change in shares since the quarter before, adjusted for stock splits and priced at the Q2 2026 value per share. Funds bought $1.5B and sold $351M; 111 added and 62 trimmed.
Schedule 13D and 13G filings on RLAY
Owners of more than 5% must file within days, so these can be newer than the 13F data.
- 2026-11-16T. Rowe Price Investment Management, Inc. SCHEDULE 13G filed by Relay Therapeutics Inc.Schedule 13G
- 2026-08-06FMR LLC SCHEDULE 13G filed by Relay Therapeutics Inc.Schedule 13G
- 2026-04-13PERCEPTIVE ADVISORS LLC SCHEDULE 13G filed by Relay Therapeutics Inc.Schedule 13G
- 2026-03-19PERCEPTIVE ADVISORS LLC SCHEDULE 13G filed by Relay Therapeutics Inc.Schedule 13G
- 2025-03-20Point72 Asset Management, L.P. SCHEDULE 13G filed by Relay Therapeutics Inc.Schedule 13G
Questions about RLAY ownership
- Who owns RLAY stock?
- 258 institutional investment managers reported RLAY positions in their Form 13F filings for Q2 2026, holding 246,758,031 shares worth $4.6B in total. SB Investment Advisers (uk) LTD reported the largest position.
- Are funds buying or selling RLAY?
- In Q2 2026, 48 managers opened new RLAY positions, 111 added, 62 trimmed and 31 sold out. Managers that filed in both quarters added a net 61,480,319 shares.
- How current is this RLAY institutional ownership data?
- It covers holdings as of the end of Q2 2026. Managers have 45 days after the quarter ends to file Form 13F (by August 14, 2026 for Q2 2026), so positions may have changed since.
From the SEC's Form 13F data sets for Q2 2026: every 13F holdings report, matched to RLAY by CUSIP. Options are left out. RLAY news and filings · RLAY insider trades · Top funds